- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002171
A Study of Viracept in HIV-Positive Women
June 23, 2005 updated by: Agouron Pharmaceuticals
A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3.
This study also examines how the body handles Viracept when given with d4T and 3TC.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Univ of Alabama at Birmingham
-
-
California
-
Los Angeles, California, United States, 90033
- Univ of Southern California / LA County USC Med Cntr
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- HIV Outpatient Clinics / LA State Univ Med Ctr
-
-
Texas
-
Houston, Texas, United States, 77009
- Baylor Univ
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria
Patients must have:
- HIV infection.
- CD4 T cell count <= 400 cells/mm3.
Exclusion Criteria
Prior Medication:
Excluded:
- Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
- Prior protease inhibitor therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 7, 2022
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
May 1, 1999
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- HIV Seropositivity
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Nelfinavir
Other Study ID Numbers
- 259D
- Study 534
- AG1343 - 534
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Nelfinavir mesylate
-
Agouron PharmaceuticalsCompletedHIV Infections | Cytomegalovirus RetinitisUnited States
-
Agouron PharmaceuticalsCompletedHIV Infections | Sarcoma, KaposiUnited States
-
Agouron PharmaceuticalsCompleted
-
Agouron PharmaceuticalsCompletedHIV Infections | Mycobacterium Avium-Intracellulare InfectionUnited States
-
National Cancer Institute (NCI)Completed
-
Bristol-Myers SquibbTerminatedHIV InfectionsUnited States, Mexico, Canada, Puerto Rico, Thailand
-
Pharmacia and UpjohnCompletedHIV InfectionsUnited States
-
Merck Sharp & Dohme LLCCompletedHIV InfectionsUnited States
-
Swiss Group for Clinical Cancer ResearchCompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Mature T-cell and Nk-cell NeoplasmsSwitzerland